FREEMAN KEVIN D 4

What Happened
Kevin D. Freeman, a director of Galectin Therapeutics, Inc. (GALT), was granted a derivative award of 60,000 shares on January 16, 2026. The Form 4 reports the acquisition as an award (transaction code A) with a reported price of $0.00. The award consists of stock options issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vests 100% on December 31, 2026. This is a grant/compensation event (not a market purchase or sale) and does not represent an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-01-16 (reported on Form 4 filed 2026-01-21)
• Transaction type/code: Award/Grant (A); derivative (stock options)
• Reported acquisition price: $0.00 (per filing)
• Vesting: 100% vests on December 31, 2026 (footnote F2)
• Plan: Issued under the 2019 Omnibus Equity Incentive Plan (footnote F1)
• Shares owned after transaction: Not specified in the provided filing
• Timeliness: Form 4 was filed 5 days after the transaction date; this is later than the typical 2-business-day reporting window for Form 4s and may be considered a late filing.

Context: This was a grant of stock options (a compensation/retention award), not an exercise or sale. Such awards do not create immediate proceeds or indicate that shares were sold; they give the insider potential future exposure depending on vesting and any exercise terms.